PepTalk 2017
PepTalk 2017
Pipeline Four Header

Cambridge Healthtech Institute’s Fourth Annual
Optimizing Expression Platforms
Transient, Stable or Both?
January 12-13, 2017 | Hilton San Diego Bayfront | San Diego, CA


Speed, limiting risk and protein quality are often cited as advantages of transient protein production (TPP), while stable transfection – the longer and more complex process – has the advantage of producing long-term expression of the biotherapeutic of interest. The rapidly increasing need for recombinant proteins necessitates further improvements in both technologies.

Cambridge Healthtech Institute’s Fourth Annual Optimizing Expression Platforms conference convenes protein expression specialists who share their experiences of the differences, tradeoffs, and improvements in producing recombinant proteins in transient or stable production systems, and who investigate their advantages and disadvantages and when to use both.

Preliminary Agenda


Transient Production


KEYNOTE PRESENTATION

Athena Wong, Ph.D., Scientist, Early Stage Cell Culture, Genentech


Rapid Production of Recombinant Proteins in CHO Cells Using Large-Scale Transfection or Stable Pools

Yves Durocher, Ph.D., Section Head, Mammalian Cell Expression - NRC Human Health Therapeutics Portfolio, National Research Council Canada

Production of AAV Gene Therapy Vector by Transient Transfection Using the iCELLis Nano

Michael Meagher, Ph.D., Vice President, Therapeutics Production & Quality, St. Jude Children’s Research Hospital

Optimizing CHO Transient Expression for Drug Discovery

Elizabeth Greene, MS, Scientist, Immune Modulation and Biotherapeutics Discovery (IMBD), Boehringer Ingelheim


CHO Cells: Improving Productivity

Chromatin Function Modifying Elements in an Industrial Antibody Production Platform

Mark Ellis, Principal Scientist, Protein Expression and Purification, UCB Pharma

Cell Line Profiling to Improve Productivity and Product Quality

Sohye Kang, Ph.D., Senior Scientist, Amgen

Product Quality and Protein Expression in CHO Cells

Pauline Smidt, Process Development Scientist, Just Biotherapeutics


Managing a Nimble Expression Lab

Transient Protein Production; Harmonizing the Process from Construct Generation through Product Characterization

Richard Altman, MS, Scientist, Protein Technologies, Amgen




For questions about the meeting, please contact:

Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5497
Email: mabrown@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com